Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

66.16USD
23 Jun 2017
Change (% chg)

$0.14 (+0.21%)
Prev Close
$66.02
Open
$66.04
Day's High
$66.39
Day's Low
$65.84
Volume
14,093,453
Avg. Vol
9,234,779
52-wk High
$66.80
52-wk Low
$55.10

Latest Key Developments (Source: Significant Developments)

Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study
Wednesday, 21 Jun 2017 05:41pm EDT 

June 21 (Reuters) - Leap Therapeutics Inc -:Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg).Leap Therapeutics Inc says under agreement, merck will be responsible for manufacturing and supplying Keytruda(reg) for clinical trials - sec filing.Leap Therapeutics Inc - agreement provides that both Leap and Merck will jointly own clinical data generated from this clinical trial.  Full Article

Leap Therapeutics announces collaboration with Merck
Wednesday, 21 Jun 2017 09:07am EDT 

June 21 (Reuters) - Leap Therapeutics Inc :Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer.Leap therapeutics inc - additional details of collaboration were not disclosed..Leap therapeutics inc - collaboration agreement is between leap and merck, through a subsidiary.Leap therapeutics inc - study is expected to begin enrolling patients in second-half of 2017.  Full Article

PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications
Tuesday, 20 Jun 2017 03:37pm EDT 

June 20 (Reuters) - PV Nano Cell Ltd::Is entering a cooperation with Merck to develop technology applications for single-crystalline metal particles.  Full Article

Serimmune announces research, development collaboration agreement with subsidiary of Merck
Tuesday, 20 Jun 2017 01:00pm EDT 

June 20 (Reuters) - Serimmune Inc::Announced a research and development collaboration agreement with a subsidiary of Merck.Under agreement terms Co will apply immune repertoire characterization platform to clinical and preclinical specimens provided by Merck.Merck will lead preclinical and clinical development and commercialization of candidates identified from collaboration.Serimmune will be eligible to receive development, regulatory milestone payments, tiered royalties on sales of any products resulting from collaboration.  Full Article

Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies
Monday, 12 Jun 2017 04:15pm EDT 

June 12 (Reuters) - Merck & Co Inc : :Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda® (pembrolizumab) in combination with other therapies.Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda (pembrolizumab) in combination with other therapies.Merck & Co Inc - patients currently enrolled in the two studies will continue to receive treatment.Merck & Co Inc - other studies of keytruda continue unchanged.Says ‍has accepted external data monitoring committee recommendation to pause new enrollment on keynote-183 and keynote-185​.Says ‍pause is to allow for additional information to be collected to better understand more reports of death in keytruda groups​.Merck & Co Inc - accepted external data monitoring committee recommendation to pause new enrollment on keynote-183 and keynote-185.  Full Article

Merck presents positive mid-stage data from breast cancer combo therapy
Monday, 5 Jun 2017 07:05am EDT 

June 5 (Reuters) - Merck & Co Inc -:New data from phase 2 i-spy 2 trial shows improved outcomes with combination of Merck’S Keytruda® (pembrolizumab) plus standard neoadjuvant therapy in patients with high-risk breast cancer.Merck - findings showed addition of keytruda increased estimated pathologic complete response rate nearly threefold in patients with tnbc (60% versus 20%).Merck & Co Inc - ‍keytruda has graduated from i-spy 2 trial for all signatures in which it was tested (tnbc, all her2-, and hr+/her2-)​.Merck & Co Inc says in keynote-006, keytruda was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma.Merck - findings showed addition of keytruda increased estimated pathologic complete response rate in patients with hr+/her2- breast cancer (34% versus 13%).Merck & Co Inc - in keytruda arm of trial, five of six patients presented with adrenal insufficiency after completion of ac.Merck & Co Inc - in keytruda arm of trial, one patient presented with adrenal insufficiency during keytruda treatment.  Full Article

Incyte Corp updates on Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Incyte Corp ::Updated data from Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda® (Pembrolizumab) demonstrate clinical activity across multiple tumor types.‍responses observed with combination of Ido1 enzyme inhibition and Anti-Pd-1 therapy support advancing into Broad Phase 3 program​.‍safety data for this novel investigational immunotherapy combination are generally similar to Keytruda monotherapy​.  Full Article

Optum and Merck collaborate to advance value-based contracting of pharmaceuticals
Thursday, 25 May 2017 02:00pm EDT 

May 25 (Reuters) - Merck & Co Inc :Optum and merck collaborate to advance value-based contracting of pharmaceuticals.Under outcomes-based risk sharing agreements, health plans & other payers reimburse drug manufacturers on basis of clinical outcomes achieved.Co, Optum, under collaboration will use real world data to develop simulate models linking payment for prescription medicines to patient health outcomes.  Full Article

Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma.Adaptimmune Therapeutics Plc - Adaptimmune is developing NY-ESO SPEAR T-cell program under a strategic collaboration agreement with GSK.  Full Article

Merck enters exclusive worldwide license agreement with Teijin Pharma
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - Merck & Co Inc ::Merck enters exclusive worldwide license agreement with Teijin Pharma for investigational antibody candidate targeting TAU.Merck & Co Inc - under terms of agreement Merck will have exclusive world-wide rights to develop, manufacture and commercialize anti-TAU antibody..Says Teijin Pharma will receive royalties on product sales and retains an option to co-promote an approved product in Japan.Merck & Co Inc - will make an upfront payment to Teijin Pharma who is also eligible to receive development, regulatory and sales milestone payments.Merck & Co Inc - Merck will make an upfront payment to Teijin Pharma who is eligible to receive development, regulatory and sales milestone payments.  Full Article

More From Around the Web

Gilead knocks out Merck patent on hepatitis C treatment

An appeals court handed biopharmaceutical company Gilead Sciences Inc a victory on Tuesday in its litigation with Merck & Co Inc over the blockbuster hepatitis C drug Sovaldi.